1	Recent advances in efficacy of corticosteroids as adjunct therapy for
2	the treatment of community-acquired pneumonia in children: a
3	systematic review and meta-analysis.
4	
5 6	Lydia Mukanhaire <sup>1,2</sup> , Junyan Wang <sup>2</sup> , Xiaoyu Zong <sup>2</sup> , Lingjian Zhang <sup>2</sup> , Xiaohui Zhou <sup>1</sup> #, Jian Gong <sup>1,2</sup> #
7	Affiliated Institutions:
8 9	1.School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, P.R. China.
10 11 12	2.Research Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, P.R. China.
13	
14	Authors email addresses:
15 16 17 18 19	Lydia Mukanhaire: lydiamukanhaire@gmail.com Junyan Wang: 3032245115@qq.com Xiaoyu Zong: 1277782939@qq.com Lingjian Zhang: 564868976@qq.com
20	#Correspondence authors:
21 22 23 24	Xiaohui Zhou, zhxh@cpu.edu.cn Jian Gong, gongjian_1979@163.com, ORCID: 0000-0002-4934-8599
25	Abstract

It has been recently shown that the adjunct use of corticosteroids in the treatment of community-acquired pneumonia shorten the time taken to reach clinical stability (time to clinical stability) in patients with community-acquired pneumonia (CAP). Considering the hyperglycemic effects of corticosteroids, there are concerns about the efficacy and safety of this therapy for children with CAP. Our objective is to evaluate the influence of recent advances in adjunct corticosteroid use and/or aerosolized NoTE: This proprint generation that has not been certified by peer review and should not be used to guide clinical practice.

duration of fever and hospital stay, and additional outcomes as the time to clinical 33 stability therapeutic efficacy, C-reactive protein and defervescence at 24, 48, and 72 34 hours after starting treatment in a well-defined cohort of children with community-35 acquired pneumonia. Therapeutic efficacy is defined as the rate of achieving clinical 36 recovery with no fever, improvement or disappearance of cough, and improved or 37 normal laboratory values. Five academic literature databases will be searched using 38 Boolean keyword searches. Articles eligible for inclusion are those that present original 39 40 research with the study topic as CAP, the study was designed as a randomized controlled trial (RCT) or clinical trial (CT) or an observational study with controls. The 41 review will result in a narrative synthesis that summarizes the effectiveness of 42 corticosteroid use in children. 43

Keywords: community-acquired pneumonia, corticosteroids, pediatrics, children,efficacy

46

### 47 Introduction

#### 48 Rationale

Pneumonia is an infection that inflames the air sacs in one or both lungs. The air sacs 49 may fill with fluid or pus, causing cough with phlegm or pus, fever, chills and difficulty 50 breathing. A variety of organisms, including bacteria, viruses and fungi can cause 51 pneumonia[1]. Pneumonia can range in seriousness from mild to life threatening[2]. It 52 is most serious for infants and young children, people older than 65, and people with 53 underlying health problems or weakened immune system[3]. Pneumonia can be broadly 54 categorized as community-acquired pneumonia, hospital acquired (nosocomial) 55 pneumonia and ventilator associated[4]. Specific pathogens such as mycoplasma 56 pneumoniae, streptococcus pneumoniae, respiratory syncytial virus and haemophilus 57 influenza type b have been found to increase the risk of hospitalization[5]. Risk factors 58 for pneumonia in children include infancy, premature birth, incomplete immunization, 59 maternal smoking or household tobacco smoke exposure, indoor air pollution, low 60 birthweight, malnutrition, lack of exclusive breastfeeding and overcrowding [6, 7]. 61 Pneumonia can be spread in multiple ways, the viruses and bacteria that are found in a 62 child's nose or throat, can infect the lungs if they are inhaled[8]. They may also spread 63 via air-borne droplets from a cough or sneeze. Also, pneumonia may spread through 64 blood during and shortly after birth[9]. The presenting features of viral and bacterial 65 pneumonia are similar[10]. However, the symptoms of viral pneumonia may be more 66 numerous than bacterial pneumonia. In children under 5 years of age, who have cough 67 and/or difficult breathing, with or without fever, pneumonia is diagnosed by the 68 presence of either fast breathing or lower chest wall in-drawing where their chest moves 69 in or retracts during inhalation[11]. Wheezing is most common in viral infections. 70

Severely ill infants may be unable to feed or drink and may also experience 71 unconsciousness, hypothermia and convulsions[12]. Pneumonia is treated with 72 antibiotics, amoxicillin being the first line of treatment[13]. Hospitalization is required 73 for severe cases of pneumonia. The most effective way to prevent pneumonia is 74 immunization against Haemophilus Influenza type b (Hib), pneumococcus, measles 75 and whooping cough(pertussis)[14]. Adequate nutrition improves the child's natural 76 defenses, starting with exclusive breastfeeding for the first six months of life[15]. 77 78 Encouraging good hygiene and providing affordable clean indoor stoves (in crowded homes) helps to reduce pneumonia infection in children[16]. In children infected with 79 HIV are given cotrimoxazole daily to decrease the risk of contracting pneumonia[17]. 80

81

#### 82 Community-acquired pneumonia

Community-acquired pneumonia (CAP) is the most common type of pneumonia. It occurs outside of hospitals and other healthcare facilities and may be caused by respiratory syncytial virus, streptococcus pneumoniae being the most common bacterial cause, bacteria like organisms like mycoplasma pneumoniae and fungi which comes in soil and bird droppings[18] [19].

88

### 89 Diagnosis of CAP

#### 90 Clinical Diagnosis

Tachypnoea, hypoxia, cough and increased work of breathing has been found to be signs of pneumonia[20]. Common clinical symptoms of CAP include cough, fever, chills, fatigue, dyspnea, rigors, and pleuritic chest pain. Depending on the pathogen, a patient's cough may be persistent and dry, or it may produce sputum[21]. The World Health Organization criteria in the diagnosis of childhood pneumonia is categorized as follows:

- In children< 2 months :> 60 breaths/minute
- In children 2-12 months:> 50 breaths/minute
- In children > 12 months :>40 breaths /minute

100

### 101 Etiological diagnosis

Virus infection, mostly by respiratory syncytial virus is more common in younger
 children[22]. In older children, the most identified pathogen is streptococcus
 pneumoniae, followed by mycoplasma and chlamydia[23]. Diagnostic modalities
 3

available for etiological diagnosis include molecular diagnostics, microscopy, culture
and antigen detection[24]. Both bacterial and viral pneumonia exhibit a wide
distribution of acute phase reactants (blood count, C reactive protein, erythrocyte
sedimentation rate)[22].Upper respiratory tract secretions are useful in virological
diagnosis. Pulmonary TB should be considered in a child presenting with severe
pneumonia or pneumonia with a known TB contact[25].

111

#### 112 Radiological diagnosis

113 The radiological signs of pneumonia overlap with those of collapse. Chest radiography 114 does not distinguish between viral and bacterial infection and is unable to detect early 115 changes in pneumonia.[7]However, chest radiography improves the diagnosis of 116 pediatric community acquired pneumonia to a certain degree and may prevent over-117 treatment with antibiotics[26].

118

#### 119 Assessment of severity

The general appearance of a child should be assessed in order to evaluate the severity 120 of the illness. Any general danger sign requires a child to be referred to a 121 hospital[27].All children less than 2 months of age with signs of pneumonia require 122 hospital admission. Inability to drink/feed, vomiting everything, convulsions, lower 123 chest in-drawing, central cyanosis, lethargy, nasal flaring, grunting, head nodding, and 124 oxygen saturation <90% are predictors of death and can be used as indicators for 125 hospitalization[28].Pulse oximetry should also be performed in all children, using a 126 pediatric wrap-around probe. A saturation of <92% or 90% at higher altitudes (>1 800m) 127

indicates the need for hospital admission and supplemental oxygen[29]. Transfer to

129 pediatric intensive care unit should be considered when: the patient is shocked, failure

to maintain rising respiratory and pulse rates with clinical evidence of severe respiratory

distress, recurrent apnea or slow irregular breathing[30]

132

# 133 Corticosteroid

134 Corticosteroids are synthetic analogs of the natural steroid hormones produced by the 135 adrenal cortex and include glucocorticoids and mineral corticoids[31]. Corticosteroids 136 work primarily by modulating transcriptional, post-transcriptional, and post-137 translational mechanisms within cellular nuclei to decrease the production of

inflammatory mediators[32] .Glucocorticoids are involved in metabolism and have
immune-suppressive, anti-inflammatory and vasoconstrictive effects while mineral
corticoids regulate electrolytes and water balance by affecting ion transplant in the
epithelial cell of renal tubules[33]. Corticosteroids are readily absorbed in the
gastrointestinal tract and are highly protein-bound. They undergo hepatic metabolism
and renal excretion[31]. Corticosteroids at high concentrations will also inhibit the
production of B cells and T cells[34].

145

# 146 How intervention might work

With the increasing reported cases of pneumonia in recent years, there has been an 147 introduction of other supportive therapies for the treatment of MP infection[35]. 148 Adjunct treatment therapies for CAP infections include the use of corticosteroids and 149 aerosolized antibiotics[36]. This might be due to the rapidly increased cases among 150 children, particularly sub-Saharan Africa and in East Asian countries such as Korea, 151 Japan, and China. As Corticosteroids have been shown to be of use as adjunct therapy 152 in the treatment of community-acquired pneumonia (CAP) it is important to note their 153 effects and physiological roles. The clinical implications of these therapies have not 154 been fully elucidated[37], thus it is imperative to note any advancements in these 155 therapies. Moreover, there is need for supportive treatment options in CAP cases with 156 clinical deterioration. However, the use of corticosteroids in children is limited 157 because of their toxicity. Methylprednisolone may cause adverse effects such as 158 159 growth retardation, weight gain, Cushingoid features and osteoporosis in children[38, 39]. Therefore, they are contraindicated for premature infants. Aerosolized antibiotics 160 have been found to provide high concentration of drugs at the target site of action in 161

162 patients with pulmonary infections[17].

163

# 164 Methods

### 165 Search strategy

166 Our search strategy is developed based on systematic review best practices. To

167 identify relevant studies, we will perform an extensive search across 5 electronic full-

text databases; Medline/PubMed, Embase, the Cochrane Library, Scopus and Web of

169 Science with no language restrictions. These databases will be searched using

170 keywords for community acquired pneumonia, corticosteroid and children as shown

in a table (Table 2). Database specific Boolean search strategies were developed and

172 follow the general format: corticosteroid terms AND (community acquired

173 pneumonia terms or children's terms) we will search articles published from January

- 174 1967 to March, 2022 using a protocol designed for this study. The search terms used
- 175 for each database are listed below:

# 176 **Table 1. Databases included in the systematic review**

Databases	URL
Web of science	www.webofknowledge.com
Medline/PubMed	pubmed.ncbi.nlm.nih.gov/
Embase	www.embase.com
Scopus	www.elsevier.com
The Cochrane Library	www.cochranelibrary.com/
World Health Organization	www.who.int/health-topics/pneumonia

177

# 178 Table 2. Search keywords

Corticosteroid terms	Children terms	
"Corticosteroids"	"Pediatrics"	
"Prednisolone"	"Infant"	
"Cortisone"	"Children"	
"Hydrocortisone"	"Pre-school child"	
"Budesonide"	"Child"	
"Dexamethasone"	"Newborn"	
"Prednisone"	"Toddler"	
"Glucocorticoids"	"Kid"	
"Mineral corticoids"	"Neonate"	
Pneumonia terms		
"Community-acquired pneumonia"		
"Mycoplasma pneumonia"		
"Pediatric-pneumonia"		

"Childhood-pneumonia"	
-----------------------	--

179

#### 180 Study selection, quality assessment, and data extraction

Studies are to be screened by two independent reviewers based on the title and 181 abstract, followed by full-text screening. The literature selection process will be 182 conducted in accordance with the Preferred Reporting Items for Systematic Reviews 183 and Meta-Analysis Protocols 2015 statement[40]. The quality of the selected studies 184 will be assessed using the Cochrane Risk of Bias Tools for RCTs and the revised Risk 185 of Bias Tool for Non-Randomized Studies for observational studies. The data 186 extraction form will include the following information: first author, year of 187 publication, population in each group, antibiotic treatment (macrolides/comparator), 188 patient characteristics (age and sex), and outcomes (durations of fever and 189 hospitalization, therapeutic efficacy, and defervescence rates at 24, 48, and 72 h after 190 starting treatment). Therapeutic efficacy is defined as the rate of achieving clinical 191 recovery with no fever, improvement or disappearance of cough, and improved or 192 normal laboratory values. Study selection, quality assessment, and data extraction to 193 be conducted. Any disagreements to be resolved through discussion. If the results of 194 the selected studies are unclear or missing, we will contact the corresponding study 195 196 investigators to obtain or confirm data

197

#### 198 Eligibility criteria

Articles that meet the following inclusion criteria will be included: (1) the study topic 199 was CAP, defined as a disease showing no clinical or radiological improvement 48-200 72 h after macrolide administration; (2) the subjects are children aged  $\leq$  12 years 201 (3) the study was designed as a randomized controlled trial (RCT), Clinical Trial (CT) 202 or an observational study with controls; (4) the intervention agent should be a 203 corticosteroid known to be active against community-acquired pneumonia, such as 204 methylprednisolone (5) the control was a placebo; and (6) at least one of the 205 predetermined outcomes was reported. Animal and preclinical studies, as well as 206 articles other than original research articles (e.g., reviews, editorials, letters, 207 conference abstracts, and comments) are to be excluded. Studies with duplicate 208 subjects (i.e., different studies using the same outcome indicators in the same number 209 210 of patients) are also going to be excluded. Our search strategy will implement no language restrictions, and non-English articles should be translated and included for 211 212 evaluation

#### 214 Data synthesis

- 215 Statistical synthesis of data(meta-analyses) will be conducted. A systematic narrative
- synthesis will be provided with the information presented in text and tables to
- summarize and explain the characteristics and findings of the included studies.
- 218 The following is a tentative outline of how we will synthesize findings. First,
- community-acquired pneumonia in children's conceptualizations will be summarized.
- 220 This will include definitions provided by community-acquired pneumonia
- researchers. Second, the antecedents of community-acquired pneumonia in children
- will be summarized. This will likely to include the grouping of corticosteroid
- therapies in the treatment of community-acquired pneumonia in children from
- literature. Finally, the evidence on recent advances in efficacy of corticosteroids and
- other supportive therapies in the treatment of community-acquired pneumonia will be
- incorporated into the theoretical framework.
- 227

### 228 Statistical analysis

We will pool the findings from the included studies such as calculated mean, standard deviation, and sample size. For outcomes presented as continuous variables, such as fever duration, hospital stay length, and therapeutic efficacy, we will calculate mean

- differences with 95% confidence intervals (CIs). For dichotomous outcomes such as
- the achievement of defervescence after 24, 48, and 72 h of treatment, we will
- calculate odds ratios (ORs) with 95%CIs. The average effect summary will be
- calculated using a random-effects model (Mantel–Haenszel method) using Review
- 236 Manager 5.3 (The Cochrane Collaboration, London, UK) including the *I*2 statistic. *I*2
- of 25%, 50%, and 75% indicated low, moderate, and high heterogeneity, respectively.
- To assess the risk of publication bias, we will use funnel plots for visual inspection;
- Egger test flow chart of the selection process to be included in meta-analysis. The
- strength of the body of evidence will be assessed using GRADE approach[41].
- 241
- 242
- 243
- 244
- 245
- 246
- 247
- 248



#### 249 Flow chart of the selection process of studies to be included in the meta-analysis

#### **Risk of publication bias** 267

- The authors have no conflicts of interest. Ideally, additional reviewers would 268 participate in study screening and data extraction. However, this is not feasible since
- 269
- this publication is not funded. 270
- 271

#### Ethics and dissemination 272

This systematic review protocol has been written following the PRISMA-P 273

- guidelines and elaboration[40, 42]. 274
- 275

#### Discussion 276

Corticosteroids may be imperative for the treatment of community-acquired 277 pneumonia. Therapeutic doses vary greatly, as do adverse effects. Patients require 278 education on what to expect with corticosteroid use, whether it be short course or 279 long-term use. Other pharmacological therapies may be necessary to counteract 280 corticosteroid-related adverse effects, such as gastric acid suppression, calcium and 281 vitamin D supplementation, and opportunistic infection prophylaxis. Providers must 282 weigh the risks versus benefits of corticosteroid use and utilize the lowest effective 283 dose for the least duration possible to avoid or minimize serious corticosteroid-284 induced toxicities. This review searches for the efficacy of corticosteroids as adjunct 285 therapy in the treatment and management of community-acquired pneumonia in 286 children. There is an ongoing unclear elucidation on the effectiveness of 287 corticosteroids use specifically in children under the ages of 5. By carefully 288 examining the published literature to date, we will contribute a novel synthesis of 289 literature compared to "corticosteroid use in community-acquired pneumonia" 290 literature that has been published before. 291

292

#### **Supporting information** 293

- 294
- 1. Table .PRISMA-P checklist (Docx)
- 2. Search strategy draft(doc) 295

# 296 Funding

297 No funding was received for this study

298

#### 299 Author Contributions

- 300 Conceptualization: Lydia Mukanhaire, Jian Gong
- 301 Methodology: Lydia Mukanhaire, Jian Gong
- 302 Supervision: Xiaohui Zhou, Jian Gong
- 303 Writing-original draft: Lydia Mukanhaire
- 304 Writing-review & editing: Junyan Wang, Xiaoyu Zong, Lingjian Zhang
- 305

#### 306 **References**

307 1. Jain, V., et al., Pneumonia Pathology, in StatPearls. 2022, StatPearls Publishing 308 Copyright © 2022, StatPearls Publishing LLC.: Treasure Island (FL). 309 2. Stamm, D.R. and H.A. Stankewicz, Atypical Bacterial Pneumonia, in StatPearls. 2022, 310 StatPearls Publishing 311 Copyright © 2022, StatPearls Publishing LLC.: Treasure Island (FL). 312 3. Ferreira-Coimbra, J., C. Sarda, and J. Rello, Burden of Community-Acquired Pneumonia and 313 Unmet Clinical Needs. Adv Ther, 2020. 37(4): p. 1302-1318. Grassi, V. and G. Romanelli, [Pneumonia: state-of-art and perspectives]. Recenti Prog Med, 314 4. 315 2006. 97(12): p. 697-703. 316 Wang, Z., et al., Investigation on Atypical Pathogens related with Community Acquired 5. 317 Pneumonia and the Factors Associated with Mycoplasma Pneumoniae Infection in Jiangsu, 318 China. Clin Lab, 2020. 66(6). 319 6. Almirall, J., et al., Risk Factors for Community-Acquired Pneumonia in Adults: A Systematic 320 Review of Observational Studies. Respiration, 2017. 94(3): p. 299-311. 321 7. Hassen, M., et al., Radiologic Diagnosis and Hospitalization among Children with Severe 322 Community Acquired Pneumonia: A Prospective Cohort Study. Biomed Res Int, 2019. 2019: p. 323 6202405. 324 Alcón, A., N. Fàbregas, and A. Torres, Pathophysiology of pneumonia. Clin Chest Med, 2005. 8. 325 26(1): p. 39-46. 326 9. Hooven, T.A. and R.A. Polin, *Pneumonia*. Semin Fetal Neonatal Med, 2017. 22(4): p. 206-213. 327 10. March Mde, F. and C.C. Sant'Anna, Signs and symptoms indicative of community-acquired 328 pneumonia in infants under six months. Braz J Infect Dis, 2005. 9(2): p. 150-5. 329 11. McCollum, E.D. and A.S. Ginsburg, Outpatient Management of Children With World Health 330 Organization Chest Indrawing Pneumonia: Implementation Risks and Proposed Solutions. Clin

331		Infect Dis, 2017. <b>65</b> (9): p. 1560-1564.
332	12.	Dean, P. and T.A. Florin, Factors Associated With Pneumonia Severity in Children: A
333		Systematic Review. J Pediatric Infect Dis Soc, 2018. 7(4): p. 323-334.
334	13.	Bielicki, J.A., et al., Effect of Amoxicillin Dose and Treatment Duration on the Need for
335		Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT
336		Randomized Clinical Trial. Jama, 2021. 326(17): p. 1713-1724.
337	14.	Leung, D.T., M.J. Chisti, and A.T. Pavia, Prevention and Control of Childhood Pneumonia and
338		<i>Diarrhea</i> . Pediatr Clin North Am, 2016. <b>63</b> (1): p. 67-79.
339	15.	Marangu, D. and H.J. Zar, Childhood pneumonia in low-and-middle-income countries: An
340		update. Paediatr Respir Rev, 2019. <b>32</b> : p. 3-9.
341	16.	Accinelli, R.A., J.A. Leon-Abarca, and D. Gozal, Ecological study on solid fuel use and
342		pneumonia in young children: A worldwide association. Respirology, 2017. 22(1): p. 149-156.
343	17.	Zar, H.J. and S.A. Madhi, Childhood pneumoniaprogress and challenges. S Afr Med J, 2006.
344		<b>96</b> (9 Pt 2): p. 890-900.
345	18.	Lanks, C.W., A.I. Musani, and D.W. Hsia, Community-acquired Pneumonia and Hospital-
346		acquired Pneumonia. Med Clin North Am, 2019. <b>103</b> (3): p. 487-501.
347	19.	Leung, A.K.C., A.H.C. Wong, and K.L. Hon, Community-Acquired Pneumonia in Children.
348		Recent Pat Inflamm Allergy Drug Discov, 2018. 12(2): p. 136-144.
349	20.	Shah, S.N., et al., Does This Child Have Pneumonia?: The Rational Clinical Examination
350		Systematic Review. Jama, 2017. <b>318</b> (5): p. 462-471.
351	21.	Lutfiyya, M.N., et al., Diagnosis and treatment of community-acquired pneumonia. Am Fam
352		Physician, 2006. <b>73</b> (3): p. 442-50.
353	22.	Claesson, B.A., et al., Etiology of community-acquired pneumonia in children based on
354		antibody responses to bacterial and viral antigens. Pediatr Infect Dis J, 1989. 8(12): p. 856-62.
355	23.	Nascimento-Carvalho, C.M., Etiology of childhood community acquired pneumonia and its
356		implications for vaccination. Braz J Infect Dis, 2001. 5(2): p. 87-97.
357	24.	Ning, G., et al., The etiology of community-acquired pneumonia among children under 5 years
358		of age in mainland China, 2001-2015: A systematic review. Hum Vaccin Immunother, 2017.
359		<b>13</b> (11): p. 2742-2750.
360	25.	Nantongo, J.M., et al., High incidence of pulmonary tuberculosis in children admitted with
361		severe pneumonia in Uganda. BMC Pediatr, 2013. 13: p. 16.
362	26.	Soudack, M., et al., The Added Value of the Lateral Chest Radiograph for Diagnosing
363		Community Acquired Pneumonia in the Pediatric Emergency Department. Isr Med Assoc J,
364		2018. <b>20</b> (1): p. 5-8.
365	27.	Ning, J., et al., Valuable hematological indicators for the diagnosis and severity assessment of
366		Chinese children with community-acquired pneumonia: Prealbumin. Medicine (Baltimore),
367		2016. <b>95</b> (47): p. e5452.
368	28.	Nascimento-Carvalho, C.M., Community-acquired pneumonia among children: the latest
369		evidence for an updated management. J Pediatr (Rio J), 2020. 96 Suppl 1: p. 29-38.
370	29.	Ambroggio, L., et al., Guideline Adoption for Community-Acquired Pneumonia in the
371		Outpatient Setting. Pediatrics, 2018. 142(4).
372	30.	Shi, T., et al., Risk factors for mortality from severe community-acquired pneumonia in
373		hospitalized children transferred to the pediatric intensive care unit. Pediatr Neonatol, 2020.
374		<b>61</b> (6): p. 577-583.

375	31.	Kapugi, M. and K. Cunningham, <i>Corticosteroids.</i> Orthop Nurs, 2019. <b>38</b> (5): p. 336-339.
376	32.	Kaplan, D.J., et al., The Simplified Science of Corticosteroids for Clinicians. JBJS Rev, 2020.
377		<b>8</b> (11): p. e2000038.
378	33.	Sibilia, J., [Corticosteroids and inflammation]. Rev Prat, 2003. 53(5): p. 495-501.
379	34.	Greaves, M.W., Anti-inflammatory action of corticosteroids. Postgrad Med J, 1976. 52(612):
380		p. 631-3.
381	35.	Wunderink, R.G. and L. Mandell, Adjunctive therapy in community-acquired pneumonia.
382		Semin Respir Crit Care Med, 2012. <b>33</b> (3): p. 311-8.
383	36.	Huang, L., X. Gao, and M. Chen, Early treatment with corticosteroids in patients with
384		<i>Mycoplasma pneumoniae pneumonia: a randomized clinical trial.</i> J Trop Pediatr, 2014. <b>60</b> (5):
385		p. 338-42.
386	37.	Wunderink, R.G., Adjunctive therapy in community-acquired pneumonia. Semin Respir Crit
387		Care Med, 2009. <b>30</b> (2): p. 146-53.
388	38.	Aljebab, F., I. Choonara, and S. Conroy, Systematic Review of the Toxicity of Long-Course Oral
389		Corticosteroids in Children. PLoS One, 2017. 12(1): p. e0170259.
390	39.	Aljebab, F., I. Choonara, and S. Conroy, Systematic review of the toxicity of short-course oral
391		corticosteroids in children. Arch Dis Child, 2016. 101(4): p. 365-70.
392	40.	Moher, D., et al., Preferred reporting items for systematic review and meta-analysis protocols
393		(PRISMA-P) 2015 statement. Syst Rev, 2015. 4(1): p. 1.
394	41.	Schwingshackl, L., G. Rüschemeyer, and J.J. Meerpohl, [How to interpret the certainty of
395		evidence based on GRADE (Grading of Recommendations, Assessment, Development and
396		<i>Evaluation)].</i> Urologe A, 2021. <b>60</b> (4): p. 444-454.
397	42.	Shamseer, L., et al., Preferred reporting items for systematic review and meta-analysis
398		protocols (PRISMA-P) 2015: elaboration and explanation. Bmj, 2015. <b>350</b> : p. g7647.